Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioseal is a fibrin sealant developed by Guangzhou Bioseal Biotechnology, designed for use as an adjunct to sutured dural repair in patients undergoing craniotomy. The product consists of two primary biological components: fibrinogen and thrombin. Upon application, thrombin facilitates the conversion of fibrinogen into fibrin, creating a stable, cross-linked matrix that adheres to tissue surfaces. This mechanism provides a watertight seal to prevent cerebrospinal fluid (CSF) leaks and supports localized hemostasis. Bioseal is currently in Phase 3 clinical development for neurosurgical indications, aiming to improve surgical outcomes by reducing the risk of postoperative CSF complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bioseal.